15
Views
0
CrossRef citations to date
0
Altmetric
RESPONSE TO LETTER

Critique on “Real-World Effectiveness of First-Line Lenvatinib Therapy in Advanced Hepatocellular Carcinoma: Current Insights” [Response to Letter]

& ORCID Icon
Pages 91-92 | Received 24 Jun 2024, Accepted 24 Jun 2024, Published online: 09 Jul 2024

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

For more information please visit our Permissions help page.